BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22616710)

  • 21. [Antibody therapy in hematology and oncology - part 1].
    Kneba M; Schrader C; Köhne H
    Med Klin (Munich); 2008 Dec; 103(12):843-59. PubMed ID: 19099214
    [No Abstract]   [Full Text] [Related]  

  • 22. [Ten years progression-free survival obtained in a patient with mantle cell lymphoma].
    Wysokińska E; Kolak A; Starosławska E; Kieszko D; Kamińska M; Surdyka D; Mocarska A; Burdan F
    Pol Merkur Lekarski; 2015 May; 38(227):280-2. PubMed ID: 26039024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vocal cord paralysis during the treatment of mantle cell lymphoma with vincristine.
    Yalin SF; Trabulus S; Yalin AS; Yalin GY; Ongoren S; Altiparmak MR
    Int J Clin Pharm; 2013 Jun; 35(3):306-8. PubMed ID: 23338712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?
    Mondello P; Steiner N; Willenbacher W; Arrigo C; Cuzzocrea S; Pitini V; Mian M
    Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):82-8. PubMed ID: 26702476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. R2-CHOP vs R-CHOP for diffuse large B-cell lymphoma.
    Fowler NH
    Clin Adv Hematol Oncol; 2014 Sep; 12(9):608-10. PubMed ID: 25654483
    [No Abstract]   [Full Text] [Related]  

  • 26. High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?
    George A; Tam CS; Seymour JF
    Leuk Lymphoma; 2013 Dec; 54(12):2575-6. PubMed ID: 23597141
    [No Abstract]   [Full Text] [Related]  

  • 27. [How to improve the efficacy of R-CHOP for indolent B-cell lymphoma?].
    Tobinai K
    Rinsho Ketsueki; 2012 Jun; 53(6):609-17. PubMed ID: 22790636
    [No Abstract]   [Full Text] [Related]  

  • 28. R-CHOP for mantle cell lymphoma.
    Klumpp TR
    J Clin Oncol; 2005 Sep; 23(27):6802; author reply 6802-3. PubMed ID: 16170194
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical Management Updates in Mantle Cell Lymphoma.
    Chen R; Sanchez J; Rosen ST
    Oncology (Williston Park); 2016 Apr; 30(4):353-60. PubMed ID: 27083466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transplantation for mantle cell lymphoma: is it the right thing to do?
    Williams ME
    Hematology Am Soc Hematol Educ Program; 2013; 2013():568-74. PubMed ID: 24319233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lenalidomide and R-CHOP in follicular lymphoma: where do we go from here?
    Gordon LI
    Lancet Haematol; 2018 Sep; 5(9):e381-e382. PubMed ID: 30172340
    [No Abstract]   [Full Text] [Related]  

  • 32. Mantle cell lymphoma (multiple lymphomatous polyposis) of gastrointestinal tract.
    Murugesh M; Sandur V; Sawalake N; Sasidharan M; Altekar S; Rathi UU; Ramadwar MR; Rathi PM
    Indian J Gastroenterol; 2007; 26(6):300-1. PubMed ID: 18431022
    [No Abstract]   [Full Text] [Related]  

  • 33. [Efficacy and prognostic analysis of frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone regimens (VR-CAP) for patients with mantle cell lymphoma].
    Cao YW; Zheng Z; Xu PP; Cheng S; Wang L; Qian Y; Zhao WL
    Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):415-419. PubMed ID: 34218585
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge.
    Skrabs C; Müller C; Agis H; Mannhalter C; Jäger U
    Leukemia; 2002 Sep; 16(9):1884-6. PubMed ID: 12200717
    [No Abstract]   [Full Text] [Related]  

  • 35. Late-onset meningeal lymphomatosis in mantle cell lymphoma controlled with chemotherapy.
    Alonso JJ; Cánovas A; Riñón MM
    Neurologia (Engl Ed); 2018 Apr; 33(3):201-202. PubMed ID: 27126565
    [No Abstract]   [Full Text] [Related]  

  • 36. The impacts of initial and relative dose intensity of R-CHOP on outcomes of elderly patients with diffuse large B-cell lymphoma.
    Kanemasa Y; Shimoyama T; Sasaki Y; Tamura M; Sawada T; Omuro Y; Hishima T; Maeda Y
    Leuk Lymphoma; 2017 Mar; 58(3):736-739. PubMed ID: 27686739
    [No Abstract]   [Full Text] [Related]  

  • 37. Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH-985 trial.
    Mounier N; Heutte N; Thieblemont C; Briere J; Gaulard P; Feugier P; Ghesquieres H; Van Den Neste E; Robu D; Tilly H; Bouabdallah R; Safar V; Coiffier B;
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):151-4. PubMed ID: 22301063
    [No Abstract]   [Full Text] [Related]  

  • 38. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
    Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
    Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma-Final analysis of JCOG0406.
    Ogura M; Yamamoto K; Morishima Y; Wakabayashi M; Tobinai K; Ando K; Uike N; Kurosawa M; Gomyo H; Taniwaki M; Nosaka K; Tsukamoto N; Shimoyama T; Fukuhara N; Yakushijin Y; Ohnishi K; Miyazaki K; Kameoka Y; Takayama N; Hanamura I; Kobayashi H; Usuki K; Kobayashi N; Ohyashiki K; Utsumi T; Kumagai K; Maruyama D; Ohmachi K; Matsuno Y; Nakamura S; Hotta T; Tsukasaki K; Nagai H
    Cancer Sci; 2023 Aug; 114(8):3461-3465. PubMed ID: 37232264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-adjusted EPOCH-R for Burkitt lymphoma.
    Hoelzer D
    Clin Adv Hematol Oncol; 2014 Nov; 12(11):777-9. PubMed ID: 25674718
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.